Boundless Bio Correlations
| BOLD Stock | USD 1.16 0.01 0.87% |
The current 90-days correlation between Boundless Bio Common and Fluoropharma Medical is 0.23 (i.e., Modest diversification). The correlation of Boundless Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Boundless Bio Correlation With Market
Modest diversification
The correlation between Boundless Bio Common and DJI is 0.22 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Boundless Bio Common and DJI in the same portfolio, assuming nothing else is changed.
Boundless | Build AI portfolio with Boundless Stock |
Moving against Boundless Stock
| 0.56 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.55 | PYC | Physiomics Plc | PairCorr |
| 0.37 | DNLI | Denali Therapeutics | PairCorr |
| 0.37 | JUMP | Leveljump Healthcare Corp | PairCorr |
| 0.33 | CMB | Cambium Bio Earnings Call This Week | PairCorr |
| 0.41 | VIVS | VivoSim Labs Symbol Change | PairCorr |
| 0.35 | VTGN | VistaGen Therapeutics | PairCorr |
| 0.32 | 75J | LEVELJUMP HEALTHCARE | PairCorr |
| 0.32 | VSTM | Verastem | PairCorr |
Related Correlations Analysis
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Boundless Stock performing well and Boundless Bio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Boundless Bio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| KLDO | 146.28 | 71.85 | 0.00 | 3.50 | 0.00 | 0.00 | 4,998 | |||
| IVBT | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| XENO | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| CALA | 21.70 | 5.80 | 0.08 | (1.58) | 20.34 | 100.00 | 280.00 | |||
| NMRD | 1.49 | (0.72) | 0.00 | 0.63 | 0.00 | 0.00 | 50.00 | |||
| SYVC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| SNNAQ | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| FPMI | 2.98 | 1.45 | 0.00 | 1.11 | 0.00 | 0.00 | 100.00 |
Boundless Bio Corporate Management
| Christian Hassig | Chief Officer | Profile | |
| James MD | Interim Officer | Profile | |
| Jamilu Rubin | Chief Officer | Profile | |
| Shailaja Kasibhatla | Senior Development | Profile | |
| Peter Krein | Senior Medicine | Profile | |
| Anthony Pinkerton | Senior Discovery | Profile | |
| Amy Berkley | Senior Team | Profile |